Globus Medical, Inc, a medical device company, focuses on the design, development, and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The company offers products that address a variety of musculoskeletal pathologies, anatomies, and surgical approaches. Its spine product portfolio includes a range of implant and surgical approach options that could be used to treat degenerative, deformity, tumor, and trauma conditions affecting the spine from the occiput to the sacrum.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Phone610-930-1800
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$712.97 million
Profitability
Miscellaneous
Employees1,800
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
Globus Medical (NYSE:GMED) Frequently Asked Questions
What is Globus Medical's stock symbol?
Globus Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "GMED."
How were Globus Medical's earnings last quarter?
Globus Medical Inc (NYSE:GMED) released its earnings results on Thursday, August, 1st. The medical device company reported $0.41 EPS for the quarter, hitting the Thomson Reuters' consensus estimate of $0.41. The medical device company had revenue of $150.55 million for the quarter, compared to the consensus estimate of $184.93 million. Globus Medical had a return on equity of 13.29% and a net margin of 19.30%. The company's revenue for the quarter was up 10.9% compared to the same quarter last year. During the same period in the previous year, the company posted $0.44 earnings per share. View Globus Medical's Earnings History.
When is Globus Medical's next earnings date?
What guidance has Globus Medical issued on next quarter's earnings?
Globus Medical issued an update on its FY19 earnings guidance on Thursday, August, 1st. The company provided earnings per share (EPS) guidance of $1.75 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.72. The company issued revenue guidance of $770-775 million, compared to the consensus revenue estimate of $768.63 million.
What price target have analysts set for GMED?
9 Wall Street analysts have issued 1 year price objectives for Globus Medical's stock. Their predictions range from $41.00 to $65.00. On average, they anticipate Globus Medical's share price to reach $55.3333 in the next year. This suggests a possible upside of 8.4% from the stock's current price. View Analyst Price Targets for Globus Medical.
What is the consensus analysts' recommendation for Globus Medical?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Globus Medical in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Globus Medical.
What are Wall Street analysts saying about Globus Medical stock?
Here are some recent quotes from research analysts about Globus Medical stock:
- 1. According to Zacks Investment Research, "Globus Medical posted a mixed second-quarter performance with earnings meeting the Zacks Consensus Estimate while revenues beating the mark. Globus Medical witnessed strength in the United States and the international regions as well as in the Musculoskeletal solutions and Enabling Technologies segments. The company has delivered strong top-line numbers for its Spine arm. Implant pull-through from ExcelsiusGPS placements and back-to-back record sales force recruiting years were the primary growth drivers. Overall, the stock has outperformed its industry in the past three months. However, the pricing scenario is persistently tough for Globus Medical." (8/6/2019)
- 2. Cantor Fitzgerald analysts commented, "We reiterate our Overweight rating on GMED with a 12-month price target of $60. We think GMED has several top-line growth drivers, including a US core market rebound, early success of emerging technologies and traction of the acquired ATEC international platform. GMED’s best-in-class profitability allows the company to invest organically or inorganically to drive top-line growth and to react to the evolving trends of the spine market. These should bring the company back to the beat-and-raise philosophy of a couple of years ago and help to push the valuation higher." (3/1/2019)
Has Globus Medical been receiving favorable news coverage?
Headlines about GMED stock have trended somewhat positive this week, according to InfoTrie. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Globus Medical earned a coverage optimism score of 0.9 on InfoTrie's scale. They also assigned media coverage about the medical device company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Globus Medical.
Are investors shorting Globus Medical?
Globus Medical saw a increase in short interest in August. As of August 15th, there was short interest totalling 2,567,600 shares, an increase of 10.1% from the July 15th total of 2,332,600 shares. Based on an average daily trading volume, of 603,800 shares, the days-to-cover ratio is presently 4.3 days. Approximately 3.4% of the company's stock are sold short. View Globus Medical's Current Options Chain.
Who are some of Globus Medical's key competitors?
Some companies that are related to Globus Medical include ResMed (RMD), Teleflex (TFX), DexCom (DXCM), Insulet (PODD), ABIOMED (ABMD), Novocure (NVCR), Hill-Rom (HRC), Haemonetics (HAE), Integra Lifesciences (IART), Penumbra (PEN), Cantel Medical (CMD), Tandem Diabetes Care (TNDM), NuVasive (NUVA), ICU Medical (ICUI) and Nevro (NVRO).
What other stocks do shareholders of Globus Medical own?
Who are Globus Medical's key executives?
Globus Medical's management team includes the folowing people:
- Mr. David C. Paul, Co-Founder & Exec. Chairman (Age 52)
- Mr. David M. Demski, CEO & Director (Age 61)
- Mr. Anthony L. Williams, Pres & Corp. Sec. (Age 48)
- Mr. David D. Davidar, Co-Founder & Director (Age 53)
- Mr. Daniel T. Scavilla, CFO, Exec. VP & Chief Commercial Officer (Age 54)
Who are Globus Medical's major shareholders?
Globus Medical's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (9.72%), BlackRock Inc. (9.72%), Vanguard Group Inc. (7.25%), Janus Henderson Group PLC (6.24%), Janus Henderson Group PLC (6.24%) and AQR Capital Management LLC (2.01%). Company insiders that own Globus Medical stock include A Brett Murphy, Anthony L Williams, Daniel T Scavilla, David C Paul, David D Davidar, David M Demski, Eric Schwartz, James R Tobin, Kelly Huller and Steven Payne. View Institutional Ownership Trends for Globus Medical.
Which institutional investors are selling Globus Medical stock?
GMED stock was sold by a variety of institutional investors in the last quarter, including Canada Pension Plan Investment Board, AQR Capital Management LLC, Allianz Asset Management GmbH, Sio Capital Management LLC, Renaissance Technologies LLC, AXA, Global Alpha Capital Management Ltd. and UBS Asset Management Americas Inc.. Company insiders that have sold Globus Medical company stock in the last year include Anthony L Williams, David C Paul, David D Davidar, James R Tobin and Kelly Huller. View Insider Buying and Selling for Globus Medical.
Which institutional investors are buying Globus Medical stock?
GMED stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Janus Henderson Group PLC, Nuance Investments LLC, Nuveen Asset Management LLC, Pembroke Management LTD, Invesco Ltd., Wells Fargo & Company MN and Paradigm Capital Management Inc. NY. View Insider Buying and Selling for Globus Medical.
How do I buy shares of Globus Medical?
Shares of GMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Globus Medical's stock price today?
One share of GMED stock can currently be purchased for approximately $51.03.
How big of a company is Globus Medical?
Globus Medical has a market capitalization of $5.06 billion and generates $712.97 million in revenue each year. The medical device company earns $156.47 million in net income (profit) each year or $1.67 on an earnings per share basis. Globus Medical employs 1,800 workers across the globe.View Additional Information About Globus Medical.
What is Globus Medical's official website?
How can I contact Globus Medical?
Globus Medical's mailing address is 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA, 19403. The medical device company can be reached via phone at 610-930-1800 or via email at [email protected]
MarketBeat Community Rating for Globus Medical (NYSE GMED)
MarketBeat's community ratings are surveys of what our community members think about Globus Medical and other stocks. Vote "Outperform" if you believe GMED will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GMED will underperform the S&P 500 over the long term. You may vote once every thirty days.
